Novel Insights into Membrane Targeting of B Cell Lymphoma by Winde, C.M. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a preprint version which may differ from the publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177846
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Review
Novel Insights into Membrane
Targeting of B Cell Lymphoma
Charlotte M. de Winde,1 Suraya Elfrink,1 and
Annemiek B. van Spriel1,*
Standard therapy of patients with B cell non-Hodgkin lymphoma (B-NHL)
predominantly consists of chemotherapy combined with anti-CD20 (e.g., ritux-
imab) immunotherapy. However, relapse of aggressive B-NHL occurs fre-
quently, and this may coincide with therapy resistance. This demonstrates
the urgent need for exploring new lymphoma-targeted therapies. We review
here recent insights in the pathophysiology of B-NHL and discuss CD20 and
three alternativemembrane targets (B cell receptor, immune checkpoints PD-1/
PD-L1, tetraspanin CD37) that are currently in the spotlight for B-NHL treat-
ment. Furthermore, we present a novel concept in which the plasmamembrane
organization of the lymphoma B cell determines the efﬁcacy of membrane-
targeted therapies, and this has consequences for treatment application and
clinical outcome in patients with B cell lymphoma.
Origin of B Cell Non-Hodgkin Lymphoma
B cells undergo several distinct phases of development, starting from pre-B cells in the bone
marrow towards ultimately their differentiation into antibody-producing plasma cells and
memory B cells. Upon encountering speciﬁc antigens, germinal centers (GCs, see Glossary)
are formed within the lymph node, where B cells undergo somatic hypermutation (SHM) and
class-switch recombination (CSR) to generate a high-afﬁnity B cell receptor (BCR). How-
ever, SHM and CSR are error-prone mechanisms, and hence the majority of B cell non-
Hodgkin lymphomas (B-NHL) arise from GC B cells [1]. These GC-derived B cell lymphomas
frequently harbor chromosomal translocations of proto-oncogenes such as BCL2, BCL6, or
MYC that are relocated under the control of the active immunoglobulin heavy chain (IgH) locus
[1,2]. Because these translocations often involve the non-productively rearranged Ig loci, most
lymphomas still express a functional BCR [1].
The GC-derived B-NHLs include follicular lymphoma (FL), Burkitt lymphoma (BL), and
diffuse large B cell lymphoma (DLBCL). DLBCL is the most prevalent type, accounting for
approximately one third of all NHL cases. Two subtypes of DLBCL have been identiﬁed:
germinal center B cell-like (GCB-) DLBCL, arising from GC B cells, and activated B cell-like
(ABC-) DLBCL, which has a post-GC origin [3]. ABC-DLBCL is characterized by constitutively
active BCR/NF-kB signaling [4], and has a worse prognosis than GCB-DLBCL [3]. The
hallmark of BL is translocation ofMYC to the IgH locus [5]. Both DLBCL and BL are aggressive
cancers, in contrast to FL which is an indolent lymphoma. However, in a large proportion of FL
cases the disease transforms into themore aggressive DLBCL [6]. Current ﬁrst-line treatment of
DLBCL consists of the combination of rituximab (anti-CD20 monoclonal antibody, mAb) with
CHOP-based chemotherapy, frequently followed by subsequent radiotherapy. BL is treated
with CHOP-based chemotherapy, sometimes combined with rituximab. For FL, a watch-and-
wait policy is frequently applied. In case of treatment indication, ﬁrst-line treatment consists of
Trends
B cell lymphoma patients still face dis-
ease relapse after standard therapy (e.
g., R-CHOP).
The cell surface of lymphoma B cells is
the most easily accessible part of the
cell, and therefore a favorable target.
In addition to CD20, alternative B cell
membrane proteins, including the B
cell receptor and tetraspanin CD37,
have gained renewed interest as ther-
apeutic targets.
Immune checkpoint inhibitors currently
tested in (pre)clinical studies for B cell
lymphoma may stimulate anti-lym-
phoma immune responses.
The expression of membrane-organiz-
ing proteins, such as tetraspanins, dif-
fers on lymphoma B cells compared to
healthy B cells.
1Department of Tumor Immunology,
Radboud Institute for Molecular Life
Sciences, Radboud University Medical
Center, Nijmegen, The Netherlands
*Correspondence:
Annemiek.vanSpriel@radboudumc.nl
(A.B. van Spriel).
TRECAN 172 No. of Pages 12
Trends in Cancer, Month Year, Vol. xx, No. yy http://dx.doi.org/10.1016/j.trecan.2017.04.006 1
© 2017 Elsevier Inc. All rights reserved.
TRECAN 172 No. of Pages 12
rituximab combined with CHOP- or CVP-based chemotherapy, with or without subsequent
radiotherapy. The exact protocol depends on the diagnosis and condition of the patient [7–9].
Although immunotherapy with rituximab has signiﬁcantly improved the clinical outcome of
patients with B cell malignancies [10,11], many patients with DLBCL [12], BL [11], or FL [13]
suffer from treatment failure or relapse. Several novel targeted therapies are currently under
(pre)clinical investigation, including therapies targeting the tumor microenvironment (reviewed
in [14]) and therapies targeting the lymphoma cells directly, either intracellular or at the
membrane (reviewed in [15]). Targeting membrane proteins to treat cancer has been exten-
sively studied by researchers and clinicians during the past two decades because the cell
surface is the most accessible part of the cell. Rituximab is a clear example of successful
antibody-based immunotherapy targeting a membrane protein. Antibody-based membrane-
targeted therapies act through different mechanisms, including direct cell death signaling,
antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC). In this review we focus on recent developments and new membrane-
targeted therapies for GC-derived B cell lymphoma (Figure 1A). Furthermore, we propose a
model illustrating the dynamic cell-surface protein landscape of lymphoma B cells that inﬂu-
ences the efﬁcacy of membrane-targeted therapies in B-NHL.
CD20 as the First B Cell-Speciﬁc Membrane Target to Treat B-NHL
Anti-CD20 mAb rituximab represents the ﬁrst mAb approved for cancer therapy by the FDA in
1997. CD20 is a four-transmembrane protein expressed on mature B cells and is involved in B
cell activation and differentiation, mainly by controlling calcium inﬂux [16]. CD20 was selected in
the early 1980s as new target for B-NHL because the majority of B-NHL cells (90%) express a
high density of CD20 at the cell surface [17]. Pro-B cells and antibody-producing plasma cells
do not express CD20, and are therefore not vulnerable to CD20 targeting. As such, the healthy
B cell pool is restored after rituximab treatment and B cell immune responses are largely
preserved.
Anti-CD20mAbs have been classiﬁed into types I and II [18], both of which induce ADCC. Type I
mAbs (e.g., rituximab and ofatumumab) are regarded as themost potent antibodies because of
their capacity to initiate CDC, in contrast to type II mAbs (e.g., obinutuzumab). Furthermore,
type II mAbsmay induce direct cell death (Figure 1B), although the exact mechanism remains to
be elucidated. Upon type I mAb binding, CD20 is redistributed to speciﬁc microdomains,
including lipid rafts and tetraspanin-enrichedmicrodomains (Box 1), which stimulates clustering
of the antibody Fc regions involved in CDC. Unfortunately, Fc receptor polymorphisms and
downregulation of CD20 caused by repeated exposure to rituximab [19] demonstrate the
urgent need for development of alternative membrane-targeted strategies.
Glossary
Antibody-dependent cell-
mediated cytotoxicity (ADCC): the
induction of cell death via binding of
an antibody to its cell surface target.
The Fc tail of the antibody engages
Fc receptor-expressing immune cells,
such as natural killer (NK) cells and
macrophages, that kill the antibody-
bound target (i.e., tumor) cell.
Burkitt lymphoma (BL): an
aggressive type of B cell non-
Hodgkin lymphoma characterized by
deregulation of the MYC proto-
oncogene.
CHOP: abbreviation for
cyclophosphamide–doxorubicin
(hydroxydaunorubicin)–vincristine
(oncovin)–prednisone, a
chemotherapeutic cocktail mostly
used to treat B cell non-Hodgkin
lymphoma patients. CHOP is often
used in combination with anti-CD20
mAb rituximab (R-CHOP).
Class-switch recombination
(CSR): the process by which the
isotype or class of immunoglobulin
produced by the B cell is switched,
for example from IgM to IgG. This
takes place via genomic changes in
the locus encoding the constant
region of the Ig heavy chain.
Complement-dependent
cytotoxicity (CDC): the induction of
cell death via activation of the
complement system (C1q binding to
the antibody), which leads to lysis of
the target (i.e., tumor) cell
membrane.
CVP: abbreviation for
cyclophosphamide–vincristine–
prednisone, a chemotherapeutic
cocktail used to treat follicular
lymphoma patients.
Diffuse large B cell lymphoma
(DLBCL): the most common and
aggressive type of B cell non-
Hodgkin lymphoma, accounting for
approximately one third of all non-
Hodgkin lymphoma cases.
Follicular lymphoma (FL): the
second most common B cell non-
Hodgkin lymphoma. FL is an indolent
cancer, but can transform into the
more aggressive DLBCL.
Germinal center: an area in B cell
follicles of secondary lymphoid
tissues where B cell proliferation,
class-switch recombination, somatic
hypermutation, and selection take
place.
Somatic hypermutation (SHM):
the process in which the Ig-encoding
DNA of mature B cells is subjected
Box 1. Plasma Membrane Microdomains
The plasma membrane is composed of multiple different proteins and lipids that are non-randomly localized into
specialized areas (microdomains). Signaling molecules, lipids, and proteins can cluster together in such organized
domains, which is crucial for efﬁcient signal transduction [73,74]. Disrupting membrane organization interferes with
several membrane-proximal signaling processes, including those involved in tumor cell survival and metastasis
(reviewed in [73]). Different types of membrane microdomains have been reported, including lipid rafts and tetra-
spanin-enrichedmicrodomains (TEMs) [75]. Lipid rafts were originally identiﬁed asmembrane fractions that are insoluble
in the strong detergent Triton X-100 [76], hence they are also deﬁned as detergent-resistant membrane domains
(DRMs). They are enriched in densely packed sphingolipids and cholesterol, and harbor glycophosphatidylinositol (GPI)-
anchored proteins, among others [77]. A different type of microdomain is formed by tetraspanin proteins (Box 2) that
associate with themselves and with speciﬁc partner molecules (including CD20, integrins, and MHCII) in clusters known
as the tetraspanin web or TEMs [78–80]. Although both TEMs and lipid rafts are detergent-resistant and present in
DRMs, they are very different domains in terms of protein composition [81,82].
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Emerging Membrane-Targeted Therapies for B Cell Lymphoma
In addition to CD20, numerous other potential membrane targets have been investigated in
lymphoma, including CD19, CD22, CD23, CD37, CD47, CD52, CD74, CD79a, CD80, HLA-
DR, and the BCR (idiotype). Furthermore, immune checkpoint inhibitors that target pro-
grammed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are currently
in the spotlight for treatment of B-NHL. Targeting of some of these cell-surface proteins with
mAbs has shown promising therapeutic efﬁcacy, but targeting others seems less suitable
because of limited speciﬁcity (e.g., CD80 and HLA-DR are very broadly expressed) or resis-
tance development (e.g., by antigen shedding or internalization). A few new mAbs directed
against B cell surface proteins currently tested in clinical trials show promising results either as
ﬁrst-line therapy in combination with rituximab or as monotherapy for heavily pretreated B-NHL
patients (e.g., anti-CD22, epratuzumab; anti-CD37, otlertuzumab; anti-CD74, milatuzumab)
(reviewed in [15]). Future antibody engineering studies, including conjugation to radio/immu-
notoxins or the generation of bispeciﬁc antibodies, may further improve their anti-lymphoma
potency. Below we will discuss recent results and focus on novel developments in targeting
membrane proteins in B-NHL, including immune checkpoints and tetraspanins (Figure 1).
Aberrant BCR Function in B-NHL
The BCR, amembrane-bound Ig, can be divided into ﬁve classes (IgG, IgD, IgM, IgA, or IgE) that
are important for antigen recognition and initiation of signaling events leading to B cell survival,
proliferation, and migration [20]. The BCR forms a complex with CD79a (or Iga) and CD79b (or
Igb) which both contain an immunoreceptor tyrosine-based activation motif (ITAM) to transmit
intracellular signaling. Upon antigen binding, the conformational state of the BCR changes to
initiate downstream signaling, but the underlying molecular mechanisms are still debated. The
‘conformation-induced oligomerization model’, which proposes that single BCRs oligomerize
upon antigen recognition [21], has recently been challenged by super-resolution studies. This
has led to convincing evidence for the ‘dissociation–activation model’ in which BCR oligomers
dissociate upon antigen binding, gaining an open conformation [22,23]. This conformational
change inﬂuences the distribution of BCR coreceptors CD19 and CD20 that interact with IgD
oligomers on resting B cells, and relocate to IgM oligomers upon B cell activation [23]. These
changes in plasma membrane organization are controlled by a superfamily of membrane-
organizing proteins, the tetraspanins (Box 2). Tetraspanin CD81 is required for reorganization of
CD19 to BCR nanoclusters, and this enables binding of signaling proteins to the intracellular
domain of CD19 and initiation of signaling downstream of the BCR [24,25].
Two modes of BCR signaling have been described. (i) Active signaling upon antigen binding to
the BCR, leading to NF-kB activation via Syk, phosphoinositide 3-kinase (PI3K), and Bruton’s
tyrosine kinase (BTK); and (ii) tonic signaling, an antigen-independent mechanism required for B
Figure 1. Current and Novel Membrane-Targeted Therapies in B Cell Lymphoma. (A) Membrane proteins used in and
explored for lymphoma-targeted therapy. Left to right: CD20; B cell receptor (BCR) with its signaling proteins CD79a/b;
CD19; PD-L1; tetraspanin CD37 with the IL-6R. (B) Targeting CD20 using mAb (e.g., rituximab) will cluster CD20 proteins
leading to tumor cell death via CDC, ADCC and/or direct apoptosis. (C) In chronic active BCR signaling [357_TD$DIFF](i), binding of (self)
antigens to the BCR triggers recruitment of Syk to the phosphorylated (P) ITAMs of CD79a/b, which leads to translocation
of PI3K to CD19. Subsequently, BTK is activated which initiates NF-kB activation via the CARMA1–BCL10–MALT1
complex resulting in lymphoma B cell survival. In tonic BCR signaling (ii), constitutive activation of PI3K in absence of (self)
antigens results in continuous signaling via the AKT pathway and lymphoma cell survival. Novel anti-idiotype therapy
strategies can directly target the BCR. Syk, PI3K, and BTK can be inhibited using small-molecule inhibitors (*). (D) Immune
checkpoint inhibitors (e.g., nivolumab, pembrolizumab, pidilimumab) bind to PD-L1 expressed on lymphoma B cells or to
PD-1 on T cells. This inhibits the immune-escape mechanism used by ABC-DLBCL and FL cells. (E) In CD37-expressing
(CD37+) B cell lymphoma (i), tumor cell death can be induced by targeting CD37-speciﬁc mAbs (IMGN529, Otlertuzumab).
By contrast, CD37-negative (CD37) B cell lymphoma (50% of DLBCL cases) (ii), shows constitutive activation of the IL-6
signaling pathway (increased p-AKT and p-STAT3). These patients may beneﬁt from a-IL-6(R) therapy. Abbreviations:
ABC, activated B cell-like; ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cyto-
toxicity; DLBCL, diffuse large B cell lymphoma; ITAM, immunoreceptor tyrosine-based activation motif.
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cell survival which occurs in mature resting B cells via activation of PI3K and protein kinase B
(AKT) (reviewed in [26]) (Figure 1C). In most GC-derived B cell lymphomas, BCR signaling is
disturbed, resulting in enhanced B cell survival and proliferation. BL shows tonic BCR signaling
(Figure 1C) via constitutive activation of the PI3K pathway driven by MYC translocation to the
IgH locus during SHM [5,27]. Chronic active BCR signaling is seen in ABC-DLBCL, as
evidenced by knockdown of BTK or components of the BCR complex that induces killing
of lymphoma cells [4]. By contrast, GCB-DLBCL cells were not killed, indicating they do not
require BCR signaling to survive. In the majority of ABC-DLBCL cases, self-antigens present in
the tumor microenvironment may drive continuous BCR stimulation (Figure 1C) [28]. The
presence of BCR clusters on ABC-DLBCL cells resembles BCR clusters observed on normal
B cells following antigen stimulation [4]. In 10% of ABC-DLBCL cases, gain-of-function
mutations in CARMA1 (also known as CARD11) were found to result in continuous NF-kB
activation [29]. Furthermore, in 20% of ABC-DLBCL cases, somatic mutations in the CD79a/
CD79b ITAM domains induced chronic active BCR signaling via inhibition of BCR endocytosis
and prevention of binding of Lyn to CD79b [4].
In FL, constitutive BCR signaling induced by presence of (self-)antigens has been found in only
20–25%of the cases [30,31], whereas themajority of FL cases (80%) bear somaticmutations in
the IgM-BCR leading to increased incorporation ofN-glycosylation sites [32,33]. If this occurs in
the antigen-binding side of the BCR it may prevent binding of (self-)antigens, but in turn can be
recognized and stimulated by lectin receptors on myeloid cells in the tumor microenvironment
[34,35]. This results in reorganization of the BCR complex (including CD19) into signaling
platforms and persistent antigen-independent signaling via Syk and BTK.
Currently, different small-molecule inhibitors targeting signaling proteins downstream of the
BCR (Syk, Lyn, PI3K, BTK) are under investigation as a novel therapy for B-NHL (reviewed in
[26]). Nevertheless, increased understanding of the conformational changes taking place in the
BCR upon antigen binding may open new opportunities to directly target the BCR itself. This
idea was originally explored in the 1980s when treatment of lymphoma patients with anti-
idiotype antibodies (targeting the variable region of the BCR) revealed promising clinical results
[36]. However, this approach required the generation of patient-speciﬁc idiotype antibodies,
hampering clinical implementation. Recently, a new tool has been developed to screen and
target tumor-speciﬁc idiotypes with small peptides linked to a pre-made IgG-Fc protein, so-
called anti-idiotype ‘peptibodies’ [37], which directly induce cell death via BCR signaling and
ADCC. Furthermore, the anti-CD79b antibody–drug conjugate polatuzumab vedotin may be
promising for the treatment of B-NHL patients [38], and is currently being investigated in clinical
trials (https://clinicaltrials.gov).
Box 2. Tetraspanins in Cancer Development
Tetraspanins are a family of four-transmembrane proteins involved in plasma membrane organization [79,82]. The
mammalian tetraspanin superfamily consists of 33 members which are expressed on almost all cells and tissues [83].
Tetraspanins consist of four transmembrane domains, a short extracellular loop (EC1), a large extracellular loop (EC2)
containing a conserved CCG region, a small intracellular loop, and two short intracellular tails [84,85]. Despite its similar
structure, CD20 cannot be classiﬁed as a genuine tetraspanin protein because it lacks the conserved CCG region in the
large extracellular loop [86]. The EC2 and transmembrane domains are involved in the formation of tetraspanin-enriched
microdomains (TEMs) by lateral associations with interaction partners, including other tetraspanins and integrins
[78–80]. Their short intracellular tails can interact with cytosolic signaling molecules (e.g., PKC, Pi4K, Rac
[63,79,85]). Through their multiple interaction partners, tetraspanins are involved in different cellular processes including
survival, proliferation, adhesion, andmigration [78]. Recently, several studies have shown that tetraspanins contribute to
cancer development and metastasis, and tetraspanin expression has been associated with patient outcome [56,87].
Therefore, tetraspanins are interesting targets for cancer therapy, and different (pre)clinical studies using tetraspanin
targeting strategies are currently ongoing (https://clinicaltrials.gov) [61,87].
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Therapeutic strategies targeting the BCR coreceptor CD19 are encouraging for patients with
relapsed/refractory B-NHL. CD19 chimeric-antigen receptors expressed by T cells (CD19-CAR
T cells) consist of an extracellular domain speciﬁc for CD19 on B-NHL cells and intracellular
domains to provide T cell stimulatory signals (e.g., CD3z andCD28). Adoptive transfer of CD19-
CAR T cells has given complete responses in 50–60% of B-NHL patients in Phase I/II clinical
trials [39]. Furthermore, blinatumomab, a CD19/CD3 bispeciﬁc T cell engager (BiTE) generated
from the antigen-binding regions of the single-chain antibodies of CD19 and CD3, is approved
by the FDA for treatment of acute lymphoblastic leukemia (ALL), and clinical results are currently
being evaluated for the treatment of other B cell malignancies including B-NHL [40]. Future
research will be necessary to determine the consequences of targeting the BCR complex in B-
NHL patients, and in particular how this changes BCR conformation and downstream
signaling.
Function and Targeting of Immune Checkpoints PD-1/PD-L1 in B-NHL
Cancer immunotherapy was chosen as the scientiﬁc breakthrough of 2013 by Science journal
[41] in view of promising results with immune checkpoint inhibitors. Immune checkpoints are
proteins that regulate immune cell activation to maintain self-tolerance and prevent autoim-
munity (reviewed in [42]). More speciﬁcally, these checkpoints play an important role in
controlling T cell priming and activation. For example, PD-1 on T cells transfers an inhibitory
signal when engaged by PD-L1 expressed by tumor cells or activated T cells.
Tumor cells may exploit these checkpoints to escape or suppress the immune system by (over)
expressing PD-L1. Currently, anti-PD-1mAbs (pembrolizumab and nivolumab) and anti-PD-L1
mAbs (atezolizumab and durvalumab) demonstrate promising clinical results in the treatment of
different solid tumors, including metastatic melanoma, urothelial carcinoma, and advanced
non-small cell lung carcinoma (reviewed in [43]). This treatment strategy has also gained more
attention in the B cell lymphoma ﬁeld (Figure 1D) (reviewed in [42]), and nivolumab has recently
been approved by the FDA for the treatment of relapsed/refractory Hodgkin lymphoma in view
of promising clinical results [44].
For DLBCL, promising clinical results have been obtained with the anti-PD-1 mAbs pidilizumab
and nivolumab [45,46], and both anti-PD-1 and anti-PD-L1 mAbs are currently being tested in
clinical trials (https://clinicaltrials.gov/). It has been shown that a subset of ABC-DLBCL tumors
(11–31%) [359_TD$DIFF]displays high expression of PD-L1, in contrast to GCB-DLBCL tumors that virtually
lack expression of PD-L1. This high PD-L1 expression has been suggested to underlie the
poorer prognosis of ABC-DLBCL patients compared to patients with GCB-DLBCL [47,48].
Because PD-L1 expression is restricted to a minority of DLBCL patients, it is likely that only this
group will beneﬁt from immune checkpoint blockade [48,49].
Although PD-L1 is rarely expressed in FL cells [42,47], FL patients may still beneﬁt from immune
checkpoint blockade because inhibition of PD-1-expressing tumor-inﬁltrating T cells by PD-L1-
expressing non-tumor cells in the tumor microenvironment can be reversed [50]. This has been
supported by clinical studies demonstrating good responses in FL patients treated with anti-
PD-1 mAbs (nivolumab and pidilizumab) [46,51]. Trials with pembrolizumab in FL patients are
currently ongoing (https://clinicaltrials.gov/). Several studies have reported that BL cells do not
express PD-L1 [47,49], and PD-1/PD-L1 checkpoint inhibitors have therefore not yet been
studied in BL. Nonetheless, the promising results of immune checkpoint inhibition in FL, which
rarely expresses PD-L1, may be translated to BL. Taken together, targeting the immune
checkpoint membrane proteins PD-1/PD-L1 seems to be a promising novel treatment option
for a selected group of ABC-DLBCL and FL patients. However, it is still debated whether
expression of PD-1/PD-L1 is of prognostic value for immune checkpoint inhibition therapy in B-
NHL [52,53].
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CD37 Rediscovered as a B Cell Membrane Target in the Treatment of B-
NHL
Tetraspanin CD37 recently regained attention as promising membrane target for mature B cell
malignancies (Box 2). CD37 expression is restricted to the immune system, with highest
abundance on mature B cells, and is absent in earlier stages of B cell development and
decreased on plasma cells [54,55]. This pattern is also reﬂected in different B cell lymphomas:
CD37 is mostly expressed on B cell malignancies derived from mature B cells (although50%
of DLBCL patients lack CD37 [56,57], as discussed below), but not in acute lymphoblastic
lymphoma and multiple myeloma [58]. Comparable to CD20, this distinct expression pattern
makes CD37 an interesting target in GC-derived B cell lymphomas. Already in 1989 the ﬁrst
CD37-targeting antibody (labeled with the radioactive isotope iodine 131) was tested in 10
refractory NHL patients, with promising clinical results [59]. However, because anti-CD20
treatment (rituximab) was introduced at the same time, anti-CD37 therapy was forgotten for
almost two decades until the development of a novel CD37-targeting mAb-derived polypeptide
re-established interest in this target [60].
Several different antibody-based CD37-targeting approaches are currently under investigation
in Phase I and II trials for chronic lymphocytic leukemia (CLL) and refractory or relapsed NHL
patients (https://clinicaltrials.gov; reviewed in [61]) (Figure 1E). Otlertuzumab (TRU-016), a
humanized, antibody-derived CD37-targeting peptide, is closest to general clinical application
in B cell malignancies. In a randomized Phase II study, relapsed CLL patients treated with the
chemotherapeutic bendamustine plus otlertuzumab showed increased progression-free sur-
vival compared to patients treated with bendamustine alone [62].
The antitumor mechanisms by which anti-CD37 agents act include ADCC, CDC, and direct
apoptosis signaling [60,63,64]. In addition, CD37–antibody complexes are known to be
internalized, and this has led to the generation of novel anti-CD37 agents coupled to toxins
(IMGN529, an anti-CD37 antibody conjugated to an anti-microtubule agent) [64] or radioactive
labels (177 [358_TD$DIFF]Lu-tetulomab) [65]. Both agents showed promising results in NHL xenograft mouse
models [64,65]. Moreover, 177Lu-tetulomab was internalized with a higher efﬁciency than
177Lu-rituximab complexes in vitro [65], and IMGN529 showed increased activity compared
to rituximab or CVP chemotherapy in a FL-derived xenograft mouse model [64]. A Phase I
clinical trial completed in July 2016 studied IMGN529 in relapsed/refractory NHL and CLL
patients (NCT01534715), and several Phase I/II clinical studies to test 177Lu-tetulomab (Beta-
lutin) are currently including NHL patients (https://clinicaltrials.gov).
Furthermore, new insights into the function of CD37 have prompted interest in combination
strategies. CD37 is important for the survival of IgG1-secreting plasma cells through the
membrane organization of a4b1 integrins and subsequent activation of the AKT signaling
pathway [66]. The intracellular tails of CD37 can be tyrosine phosphorylated, leading to the
initiation of apoptotic signaling via the N-terminal immunoreceptor tyrosine-based inhibition
motif (ITIM)-like domain, and opposing survival signaling via its C-terminal ITAM domain [63].
Both pathways are induced by the CD37-targeting mAb-derived polypeptide SMIP-016 which
was the basis for the development of TRU-016. Although signaling to apoptosis is the most
prominent, the efﬁciency of CD37 targeting could be improved using combination therapy with
pro-survival PI3K inhibitors [63].
Importantly, recent studies revealed that 50% of DLBCL tumors are negative for CD37
expression, and its loss is a potential risk factor for R-CHOP resistance and poor survival rates
independent of the International Prognostic Index (IPI) [56,57]. The underlying mechanism
involves enhanced activation of the IL-6 signaling pathway in CD37-negative lymphomas [56].
IL-6 is known to be involved in the development of many cancers, including hematological
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Key:
Figure 2. Plasma Membrane Organization of Lymphoma B cells Determines the Efﬁcacy of Membrane-Targeted Therapies. The cell membrane (light area) is highly
organized into specialized microdomains (dark area) that are formed by dynamic homotypic (e.g., CD20–CD20) and heterotypic (e.g., CD19–CD81) protein–protein
interactions. Upon ligand–receptor binding (e.g., IL-6 to IL-6R), induction of a conformational change can lead to rearrangement of protein–protein interactions and
reorganization of the membrane landscape. Lymphoma B cells have a disrupted membrane protein organization, for example as a result of constant activation of the B
cell receptor (BCR) by (self-)antigens, overexpression of PD-L1, or loss of tetraspanin CD37. In addition, BCR activation results in CD20 dissociation and redistribution,
and anti-CD20 targeted therapy using rituximab induces CD20 clustering. These data support a model in which the microdomain organization of lymphoma cells
determines the efﬁcacy of membrane-targeted therapies, which has important implications for treatment application and clinical outcome.
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malignancies, and several IL-6-targeting strategies have been developed (reviewed in [67,68]).
Based on these studies, inhibition of IL-6 signaling (using mAb anti-IL-6 siltuximab or anti-IL-6R
tocilizumab) may represent a potential new treatment strategy for patients with CD37-negative
DLBCL (Figure 1E).
Dynamic Protein Interactions Shape the Organization of the B Cell
Membrane
Proteins in the plasma membrane are not randomly distributed, and instead are localized to
speciﬁcmicrodomains (Box 1). One of the ﬁrst models of membrane protein organization on the
B cell membrane was published two decades ago [69]. Using ﬂow cytometry energy transfer
(FCET) it was shown that CD20 interacts with tetraspanins CD53, CD81, and CD82 on a
lymphoma B cell line. In addition, confocal microscopy [70] and coimmunoprecipitation [71]
revealed that CD20 also clusters with the BCR in specializedmicrodomains, indicating that they
are localized in lipid rafts or tetraspanin microdomains (Box 1). The BCR dissociates fromCD20
to distinct lipid rafts upon stimulation, and is subsequently internalized [70]. A direct interaction
between CD20 and the BCR was recently conﬁrmed using proximity-ligation assay [23]. It was
shown that CD20 (similar to CD19) interacts with different BCR classes (IgD/IgM) on resting and
antigen-activated human B cells, demonstrating redistribution of CD20 upon BCR stimulation.
CD20 has been shown to interact with several tetraspanins (CD53, CD81, and CD82) [69],
although CD37 was not studied. Recently we discovered that both protein and mRNA
expression of CD20 and CD37 on lymphoma B cells are correlated [57]. Although this is in
line with the inferior outcome of CD37-negative DLBCL patients upon R-CHOP therapy, the
prognostic signiﬁcance of CD37 seems to be independent of CD20 mRNA levels [57]. Further
research is necessary to verify a possible direct interaction and co-expression patterns of CD37
and CD20 in B-NHL cases.
These studies indicate that the organization of the B cell membrane is shaped by dynamic
protein–protein interactions that are subject to change upon B cell activation. This protein
organization is not only important for B cell function but also for the efﬁcacy of membrane-
targeted therapies, as illustrated by clustering of CD20 upon rituximab binding [18]. Likewise,
CD37-targeting using SMIP-016 resulted in translocation into microdomains, and translocation
was required for efﬁcient tumor cell apoptosis [63]. On lymphoma B cells, changes in mem-
brane protein expression (e.g., absence of CD37) or protein clustering (e.g., conformational
changes of the BCR upon binding of self-antigens) will change the protein organization and
interactions at the plasma membrane. Based on these studies we propose that the changed
cell-surface protein landscape of lymphoma B cells has consequences for the efﬁcacy and
application of membrane-targeted therapies (Figure 2). Moreover, targeted therapies may alter
dynamic protein–protein interactions, affecting plasma membrane organization and down-
stream signaling.
Concluding Remarks
Many patients with B-NHL still face treatment failure or relapse upon standard therapy,
emphasizing the urgent need for new treatment options. The plasma membrane is the most
easily accessible part of the tumor cell, and exposes a variety of different proteins which may
serve as treatment targets. We have discussed the widely studied target CD20 and three
alternative membrane targets (BCR, PD-L1, and CD37) that are currently under investigation in
clinical trials to treat B-NHL. Furthermore, patients with CD37-negative lymphoma B cells have
a dismal prognosis and may beneﬁt from anti-IL-6(R)-targeted therapy.
Outstanding Questions
What is the effect of membrane-tar-
geted therapies on the plasma mem-
brane organization of lymphoma cells?
How does this alter signal transduction
pathways and lymphoma cell death,
and what is the effect on clinical
outcome?
Is it possible to modify plasma mem-
brane organization by targeting the tet-
raspanin web, and thereby induce
downstream signaling that drives lym-
phoma cell eradication?
What is the effect of BCR-targeted
therapies on the conformational state
of the BCR, and on the BCR complex
formation with partner proteins, includ-
ing CD19, CD20, and CD81?
What is the predictive value of PD-L1
expression upon treatment with
immune checkpoint inhibitors as mea-
sured by clinically relevant outcome
parameters such as overall survival
and progression-free survival?
Will Burkitt lymphoma patients beneﬁt
from immune checkpoint inhibitors
given the lack of PD-L1 on these lym-
phoma cells? PD-L1-based therapy
may target immune cells in the tumor
microenvironment, and thereby elimi-
nate the tumor-induced immune
suppression.
One half of patients with DLBCL have
lost CD37 expression on the tumor
cells. Is CD37 deﬁciency also apparent
in other B cell malignancies (e.g., FL,
BL, CLL) and of prognostic value? This
may have implications for inclusion cri-
teria, stratiﬁcation, and outcome of
clinical trials studying CD37-targeted
therapies.
Is targeting of IL-6, IL-6R, or down-
stream signaling proteins (JAK,
STAT3) effective in patients with
CD37-negative DLBCL that shows
increased activation of the IL-6
pathway?
Which (membrane-targeting) combi-
nation therapies would be most effec-
tive to treat B cell lymphoma?
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Membrane proteins interact with each other and thereby facilitate various cell biological
processes, including initiation of downstream signaling. B cell activation will affect these protein
interactions through induction of new interactions, more clustering, or alternatively by prevent-
ing speciﬁc interactions. Evidence is accumulating that lymphoma B cells contain aberrant cell-
surface protein expression and organization, and this has important consequences for both the
application and outcome of membrane-targeted therapy for B-NHL patients.
We are only at the beginning of understanding the membrane organization of normal and
malignant B cells, and further research will be necessary to address the outstanding issues in
this new and exciting ﬁeld (see Outstanding Questions). In particular, recent advances in super-
resolution microscopy now enable imaging the membrane composition of lymphoma cells at
the nanoscale level [72]. Taking into account that lymphomas are heterogeneous tumors [2],
targetingmembrane proteins asmonotherapy will probably not be sufﬁcient for complete tumor
eradication. Thus, the use of combination therapies, such as immuno-chemotherapy and the
additional use of small-molecule inhibitors, will be important in the future treatment of B cell
non-Hodgkin lymphoma.
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